Company Focus
Sun Pharmaceuticals
Latest Sun Pharmaceuticals News
Generics
In a significant move to expand its oncology footprint in the United States, Indian major Dr Reddy’s Laboratories has announced the launch of Bosutinib 400mg tablets, the generic equivalent of Pfizer’s blockbuster drug Bosulif, used in the treatment of chronic myeloid leukemia (CML). 15 June 2026
Related News
Insights
Company Spotlight
A clinical-stage biotechnology company developing therapies aimed at achieving a functional cure for chronic hepatitis B virus (HBV) infection. Arbutus Biopharma combines antiviral drug development with proprietary lipid nanoparticle (LNP) delivery technology used in nucleic acid medicines.
Latest News & Features of interest to Sun Pharmaceuticals
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted Japanese pharma major Shionogi’s supplemental New Drug Application (sNDA) for Fetroja (cefiderocol) for the treatment of pediatric patients (at least 26 weeks of gestational age) with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) and complicated urinary tract infections (cUTI), including pyelonephritis, caused by certain Gram-negative microorganisms. 20 July 2026
Pharmaceutical
US pharma major Bristol Myers Squibb is expanding its partnership with NVIDIA, with plans to deploy an NVIDIA DGX SuperPOD built on DGX Vera Rubin NVL72 systems to support AI-led drug discovery and development. 20 July 2026
Pharmaceutical
The Gates Medical Research Institute (Gates MRI) has reached a milestone agreement with the Serum Institute of India (SII) to manufacture M72/AS01E, a novel tuberculosis (TB) vaccine candidate. 20 July 2026
Pharmaceutical
Last week saw AstraZeneca sign an accord with China’s Dizal Pharmaceutical for rights to the latter’s lung cancer drug Zegfrovy. Biogen released new Phase II data its Alzheimer’s candidate diranersen that raised questions. Celcuity won US Food and Drug Administration (FDA) for its investigational breast cancer drug Revtorpyk and Merck & Co announced FDA approval for its oral PCK9 cholesterol drug Lipfendra. Eli Lilly revealed plans to acquire mental health biotech AtaiBeckley for an upfront $2.8 billion. 19 July 2026
Pharmaceutical
Australia’s CSL Limited subsidiary CSL Seqirus has started shipping influenza vaccines to health care providers in the USA, helping them get prepared for the upcoming flu season, to target the H3N2 subclade K strain that drove last season’s historic surge. 18 July 2026
Pharmaceutical
The US Food and Drug Administration’s (FDA) approval of Utebzi (tebipenem pivoxil) gives physicians the first oral carbapenem option for adults with complicated urinary tract infections (cUTIs), including pyelonephritis, who have limited or no alternative oral treatment options. 17 July 2026
Pharmaceutical
Swiss pharma giant Novartis today announced that the US Food and Drug Administration (FDA) has granted traditional approval for Fabhalta (iptacopan) to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression. 17 July 2026
Biotechnology
UK biotech company Mission Therapeutics has agreed to hand its acute kidney injury candidate MTX652 to Australian renal specialist Dimerix in a deal that could bring the Cambridge-based firm up to $292 million, freeing it to concentrate on a central nervous system pipeline led by a Parkinson's disease drug. 17 July 2026
Pharmaceutical
US pharma major Eli Lilly has agreed to acquire AtaiBeckley in a deal worth up to $3.8 billion in one of the largest big pharma moves yet into psychedelic-based mental health medicines. 16 July 2026
Biotechnology
US clinical-stage biopharma Arbutus Biopharma saw its shares rise 4% to $4.70 in premarket activity today, as it announced initiation of patent infringement action. 16 July 2026
Latest In Brief for Sun Pharmaceuticals
Pharmaceutical
Shares of Indian drug major Sun Pharmaceutical Industries declined sharply in trade on the Bombay Stock Exchange, as investor sentiment turned cautious following reports of a potential large acquisition. 10 April 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze